Your location:Home > Company Profile > Technology Overview
Company Profile


     Lisen's pioneering quantitative chromogenic imprinted gene in situ hybridization (QCIGISH) technology utilizes the information from imprinted genes for quantitative analysis and diagnostics. Not only is the technology helpful for tumor screening and treatment, but it also offers great potential for new drug research and development.

     There have been 5,000 tumor tissues and cytological samples gathered which have been proceeded for analysis in Lisen's epigenetics laboratory. Tumor samples were obtained from various sources including those from thyroid, breast, pancreas, lung, stomach, colorectal, esophagus, skin, bladder, prostate, lymph and liver cancer types. The results supported the wide range of potential applications of Lisen's imprinted gene detection technology which are detailed as follows:

High-Risk Population Screening

     Non-invasive or minimally invasive techniques such as urine exfoliated cells, sputum exfoliated cells and fingertip blood samples can be collected for the cancer high-risk population such as the elderly, people with long-term radiation exposure and those with family history of cancer. Through the imprinted gene detection technology, early discovery and treatment can be achieved which would help in reducing cancer mortality, alleviating medical costs and improve public health in general.

Presurgical Diagnosis

     Through fine-needle aspiration, endoscopic cell detection and biopsy, cell samples of cancer patients can be obtained. Utilizing the imprinted gene detection technology, benign and malignant tumors can be clearly identified and tumor metastasis can be assessed. In addition, multi-imprinted gene combination can be used for tumor classification as well as a medical basis to support further patients' treatment.

Medication Guidance and Personalized Treatment

     Based on the cytological samples of tumor patients obtained in the process of preoperative diagnosis, the individual characteristics of the patients' imprinted gene expression can be analyzed. Specific drug medication appropriate for such imprinted gene signatures can be formulated ensuring a highly precise medical treatment.

Prognosis Evaluation

     Cancer prognosis and recurrence can be evaluated by analyzing the imprinted genes related to prognosis from the cytological samples of tumor patients during the preoperative diagnosis.

New Drug Research and Development

     The imprinted gene detection signatures from various cancer types can be used as a powerful tool and platform in driving various sensitivity screening experiments for drug design and development.


                             Dr. Zhou Ning, Lisen's CEO , explaining the company's novel technology 

                             during his interview with Zhu Yi, a famous CCTV host.